Peripheral myelin protein 22 is regulated post-transcriptionally by miRNA-29a

GLIA

Volumn 57, Issue 12, 2009, Pages 1265-1279

  Verrier, Jonathan D ^a   Lau, Pierre ^b   Hudson, Lynn ^b   Murashov, Alexander K ^c   Renne, Rolf ^a   Notterpek, Lucia ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Gene regulation; MicroRNA; Myelin; Myelination; Schwann cell

Indexed keywords

ARGONAUTE 2 PROTEIN; MICRORNA; PERIPHERAL MYELIN PROTEIN 22; RIBONUCLEASE III;

3' UNTRANSLATED REGION; ANIMAL CELL; ARTICLE; BIOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; GENE EXPRESSION REGULATION; GENE REPRESSION; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; REPORTER GENE; SCHWANN CELL; TRANSCRIPTION REGULATION;

ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; EUKARYOTIC INITIATION FACTOR-2; GENE EXPRESSION REGULATION; IMMUNOPRECIPITATION; MEMBRANE PROTEINS; MICRORNAS; MYELIN PROTEINS; NERVE CRUSH; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RATS; RIBONUCLEASE III; RNA, SMALL INTERFERING; SCHWANN CELLS; SCIATIC NERVE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION;

EID: 70349089243     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.20846     Document Type: Article

References (66)

1. Amici SA, Dunn WA Jr, Murphy AJ, Adams NC, Gale NW, Valenzuela DM, Yancopoulos GD, Notterpek L. 2006. Peripheral myelin protein 22 is in complex with alpha6beta4 integrin, and its absence alters the Schwann cell basal lamina. J Neurosci 26:1179-1189.
2. Aston C, Jiang L, Sokolov BP. 2005. Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. Mol Psychiatry 10:309-322.
3. Baechner D, Liehr T, Hameister H, Altenberger H, Grehl H, Suter U, Rautenstrauss B. 1995. Widespread expression of the peripheral myelin protein-22 gene (PMP22) in neural and non-neural tissues during murine development. J Neurosci Res 42:733-741.
4. Bagga S, Bracht J, Hunter S, Massirer K, Holtz J, Eachus R, Pasquinelli AE. 2005. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell 122:553-563.
5. Berger P, Niemann A, Suter U. 2006. Schwann cells and the pathogenesis of inherited motor and sensory neuropathies (Charcot-Marie-Tooth disease). Glia 54:243-257.
6. Bhanji RA, Eystathioy T, Chan EK, Bloch DB, Fritzler MJ. 2007. Clinical and serological features of patients with autoantibodies to GW/P bodies. Clin Immunol 125:247-256.
7. Blenkiron C, Miska EA. 2007. miRNAs in cancer: Approaches, aetiology, diagnostics and therapy. Hum Mol Genet 16 Spec No 1:R106-R113.
8. Bosse F, Brodbeck J, Muller HW. 1999. Post-transcriptional regulation of the peripheral myelin protein gene PMP22/gas3. J Neurosci Res 55:164-177.
9. Bosse F, Hasenpusch-Theil K, Kury P, Muller HW. 2006. Gene expression profiling reveals that peripheral nerve regeneration is a consequence of both novel injury-dependent and reactivated developmental processes. J Neurochem 96:1441-1457.
10. Chance PF, Alderson MK, Leppig KA, Lensch MW, Matsunami N, Smith B, Swanson PD, Odelberg SJ, Disteche CM, Bird TD. 1993. DNA deletion associated with hereditary neuropathy with liability to pressure palsies. Cell 72:143-151.
11. Chen JF, Murchison EP, Tang R, Callis TE, Tatsuguchi M, Deng Z, Rojas M, Hammond SM, Schneider MD, Selzman CH, Meissner G, Patterson C, Hannon GJ, Wang DZ. 2008. Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc Natl Acad Sci USA 105:2111-2116.
12. Cheng L, Mudge AW. 1996. Cultured Schwann cells constitutively express the myelin protein P0. Neuron 16:309-319.
13. Clemence A, Mirsky R, Jessen KR. 1989. Non-myelin-forming Schwann cells proliferate rapidly during Wallerian degeneration in the rat sciatic nerve. J Neurocytol 18:185-192.
14. Clop A, Marcq F, Takeda H, Pirottin D, Tordoir X, Bibe B, Bouix J, Caiment F, Elsen JM, Eychenne F, Larzul C, Laville E, Meish F, Milenkovic D, Tobin J, Charlier C, Georges M. 2006. A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat Genet 38:813-818.
15. Damiani D, Alexander JJ, O'Rourke JR, McManus M, Jadhav AP, Cepko CL, Hauswirth WW, Harfe BD, Strettoi E. 2008. Dicer inactivation leads to progressive functional and structural degeneration of the mouse retina. J Neurosci 28:4878-4887.
16. Davis TH, Cuellar TL, Koch SM, Barker AJ, Harfe BD, McManus MT, Ullian EM. 2008. Conditional loss of Dicer disrupts cellular and tissue morphogenesis in the cortex and hippocampus. J Neurosci 28:4322-4330.
17. Ding L, Han M. 2007. GW182 family proteins are crucial for microRNA-mediated gene silencing. Trends Cell Biol 17:411-416.
18. Dracheva S, Davis KL, Chin B, Woo DA, Schmeidler J, Haroutunian V. 2006. Myelin-associated mRNA and protein expression deficits in the anterior cingulate cortex and hippocampus in elderly schizophrenia patients. Neurobiol Dis 21:531-540.
19. Eystathioy T, Chan EK, Tenenbaum SA, Keene JD, Griffith K, Fritzler MJ. 2002. A phosphorylated cytoplasmic autoantigen, GW182, associates with a unique population of human mRNAs within novel cytoplasmic speckles. Mol Biol Cell 13:1338-1351.
20. Garbay B, Heape AM, Sargueil F, Cassagne C. 2000. Myelin synthesis in the peripheral nervous system. Prog Neurobiol 61:267-304.
21. Gould RM, Freund CM, Palmer F, Feinstein DL. 2000. Messenger RNAs located in myelin sheath assembly sites. J Neurochem 75:1834-1844.
22. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. 2007. MicroRNA targeting specificity in mammals: Determinants beyond seed pairing. Mol Cell 27:91-105.
23. Hammond SM. 2006. MicroRNA therapeutics: A new niche for antisense nucleic acids. Trends Mol Med 12:99-101.
24. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, Kloos RT, Croce CM, de la Chapelle A. 2005. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 102:19075-19080.
25. Hebert SS, Horre K, Nicolai L, Papadopoulou AS, Mandemakers W, Silahtaroglu AN, Kauppinen S, Delacourte A, De Strooper B. 2008. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci USA 105:6415-6420.
26. Hengst U, Cox LJ, Macosko EZ, Jaffrey SR. 2006. Functional and selective RNA interference in developing axons and growth cones. J Neurosci 26:5727-5732.
27. Islamov RR, Chintalgattu V, Pak ES, Katwa LC, Murashov AK. 2004. Induction of VEGF and its Flt-1 receptor after sciatic nerve crush injury. Neuroreport 15:2117-2121.
28. Jessen KR, Mirsky R. 2008. Negative regulation of myelination: Relevance for development, injury, and demyelinating disease. Glia 56:1552-1565.
29. Jing Q, Huang S, Guth S, Zarubin T, Motoyama A, Chen J, Di Padova F, Lin SC, Gram H, Han J. 2005. Involvement of micro-RNA in AU-rich element-mediated mRNA instability. Cell 120:623-634.
30. Karginov FV, Conaco C, Xuan Z, Schmidt BH, Parker JS, Mandel G, Hannon GJ. 2007. A biochemical approach to identifying microRNA targets. Proc Natl Acad Sci USA 104:19291-19296.
31. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. 2007. The role of site accessibility in microRNA target recognition. Nat Genet 39:1278-1284.
32. Lau P, Verrier JD, Nielsen JA, Johnson KR, Notterpek L, Hudson LD. 2008. Identification of dynamically regulated microRNA and mRNA networks in developing oligodendrocytes. J Neurosci 28:11720-11730.
33. Lian S, Jakymiw A, Eystathioy T, Hamel JC, Fritzler MJ, Chan EK. 2006. GW bodies, microRNAs and the cell cycle. Cell Cycle 5:242-245.
34. Liu J, Valencia-Sanchez MA, Hannon GJ, Parker R. 2005. MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies. Nat Cell Biol 7:719-723.
35. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(- Delta Delta C(T)) Method. Methods 25:402-408.
36. Lupski JR, Garcia CA. 1992. Molecular genetics and neuropathology of Charcot-Marie-Tooth disease type 1A. Brain Pathol 2:337-349.
37. Maier M, Berger P, Nave KA, Suter U. 2002. Identification of the regulatory region of the peripheral myelin protein 22 (PMP22) gene that directs temporal and spatial expression in development and regeneration of peripheral nerves. Mol Cell Neurosci 20:93-109.
38. Maier M, Castagner F, Berger P, Suter U. 2003. Distinct elements of the peripheral myelin protein 22 (PMP22) promoter regulate expression in Schwann cells and sensory neurons. Mol Cell Neurosci 24:803-817.
39. Manfioletti G, Ruaro ME, Del Sal G, Philipson L, Schneider C. 1990. A growth arrest-specific (gas) gene codes for a membrane protein. Mol Cell Biol 10:2924-2930.
40. Mattick JS, Makunin IV. 2005. Small regulatory RNAs in mammals. Hum Mol Genet 14 Spec No 1:R121-R132.
41. McBride JL, Boudreau RL, Harper SQ, Staber PD, Monteys AM, Martins I, Gilmore BL, Burstein H, Peluso RW, Polisky B, Carter BJ, Davidson BL. 2008. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi. Proc Natl Acad Sci USA 105:5868-5873.
42. Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschl T. 2004. Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell 15:185-197.
43. Murashov AK, Chintalgattu V, Islamov RR, Lever TE, Pak ES, Sierpinski PL, Katwa LC, Van Scott MR. 2007. RNAi pathway is functional in peripheral nerve axons. FASEB J 21:656-670.
44. Nobbio L, Vigo T, Abbruzzese M, Levi G, Brancolini C, Mantero S, Grandis M, Benedetti L, Mancardi G, Schenone A. 2004. Impairment of PMP22 transgenic Schwann cells differentiation in culture: Implications for Charcot-Marie-Tooth type 1A disease. Neurobiol Dis 16:263-273.
45. Notterpek L, Roux KJ, Amici SA, Yazdanpour A, Rahner C, Fletcher BS. 2001. Peripheral myelin protein 22 is a constituent of intercellular junctions in epithelia. Proc Natl Acad Sci USA 98:14404-14409.
46. Notterpek L, Ryan MC, Tobler AR, Shooter EM. 1999. PMP22 accumulation in aggresomes: Implications for CMT1A pathology. Neurobiol Dis 6:450-460.
47. O'Rourke JR, Georges SA, Seay HR, Tapscott SJ, McManus MT, Goldhamer DJ, Swanson MS, Harfe BD. 2007. Essential role for Dicer during skeletal muscle development. Dev Biol 311:359-368.
48. Pareek S, Notterpek L, Snipes GJ, Naef R, Sossin W, Laliberte J, Iacampo S, Suter U, Shooter EM, Murphy RA. 1997. Neurons promote the translocation of peripheral myelin protein 22 into myelin. J Neurosci 17:7754-7762.
49. Pareek S, Suter U, Snipes GJ, Welcher AA, Shooter EM, Murphy RA. 1993. Detection and processing of peripheral myelin protein PMP22 in cultured Schwann cells. J Biol Chem 268:10372-10379.
50. Patel PI, Roa BB, Welcher AA, Schoener-Scott R, Trask BJ, Pentao L, Snipes GJ, Garcia CA, Francke U, Shooter EM, Lupski JR, Suter U. 1992. The gene for the peripheral myelin protein PMP-22 is a candidate for Charcot-Marie-Tooth disease type 1A. Nat Genet 1:159-165.
51. Pillai RS, Bhattacharyya SN, Artus CG, Zoller T, Cougot N, Basyuk E, Bertrand E, Filipowicz W. 2005. Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science 309:1573-1576.
52. Roa BB, Garcia CA, Lupski JR. 1991. Charcot-Marie-Tooth disease type 1A: Molecular mechanisms of gene dosage and point mutation underlying a common inherited peripheral neuropathy. Int J Neurol 25/26:97-107.
53. Roux KJ, Amici SA, Notterpek L. 2004. The temporospatial expression of peripheral myelin protein 22 at the developing blood-nerve and blood-brain barriers. J Comp Neurol 474:578-588.
54. Ryan MC, Shooter EM, Notterpek L. 2002. Aggresome formation in neuropathy models based on peripheral myelin protein 22 mutations. Neurobiol Dis 10:109-118.
55. Scherer SS. 1997. The biology and pathobiology of Schwann cells. Curr Opin Neurol 10:386-397.
56. Schneider C, King RM, Philipson L. 1988. Genes specifically expressed at growth arrest of mammalian cells. Cell 54:787-793.
57. Snipes GJ, Suter U, Welcher AA, Shooter EM. 1992. Characterization of a novel peripheral nervous system myelin protein (PMP-22/SR13). J Cell Biol 117:225-238.
58. Suter U, Snipes GJ, Schoener-Scott R, Welcher AA, Pareek S, Lupski JR, Murphy RA, Shooter EM, Patel PI. 1994. Regulation of tissue-specific expression of alternative peripheral myelin protein-22 (PMP22) gene transcripts by two promoters. J Biol Chem 269:25795-25808.
59. Svaren J, Meijer D. 2008. The molecular machinery of myelin gene transcription in Schwann cells. Glia 56:1541-1551.
60. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. 2006. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 20:515-524.
61. van Dartel M, Hulsebos TJ. 2004. Characterization of PMP22 expression in osteosarcoma. Cancer Genet Cytogenet 152:113-118.
62. van Rooij E, Olson EN. 2007. MicroRNAs: Powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 117:2369-2376.
63. Wegner M. 2000. Transcriptional control in myelinating glia: The basic recipe. Glia 29:118-123.
64. Wu L, Belasco JG. 2008. Let me count the ways: Mechanisms of gene regulation by miRNAs and siRNAs. Mol Cell 29:1-7.
65. Yang Z, Jakymiw A, Wood MR, Eystathioy T, Rubin RL, Fritzler MJ, Chan EK. 2004. GW182 is critical for the stability of GW bodies expressed during the cell cycle and cell proliferation. J Cell Sci 117(Pt 23):5567-5578.
66. Zoidl G, Blass-Kampmann S, D'Urso D, Schmalenbach C, Muller HW. 1995. Retroviral-mediated gene transfer of the peripheral myelin protein PMP22 in Schwann cells: Modulation of cell growth. EMBO J 14:1122-1128.